Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 81-90 of 411 for multiple

Edit search filters
  1. A Study To Evaluate The Safety, Tolerance And Anti-tumor Activity Of SAR442257 In Patients With Relapsed/Refractory Multiple Myeloma And Relapsed/Refractory Non-Hodgkin Lymphoma

    Rochester, MN

  2. Venetoclax, Ixazomib Citrate, And Dexamethasone In Treating Patients With Relapsed Multiple Myeloma

    Rochester, MN

  3. A Study Of Pomalidomide, Ixazomib Citrate, And Dexamethasone In Treating Patients With Previously Treated Multiple Myeloma Or Plasma Cell Leukemia

    Rochester, MN

  4. S1211, Bortezomib, Dexamethasone, And Lenalidomide With Or Without Elotuzumab In Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma

    Jacksonville, FL, Rochester, MN

  5. A Study To Evaluate EAA181 To Treat Newly-diagnosed Multiple Myeloma

    La Crosse, WI, Rochester, MN

  6. A Study To Evaluate The Safety Of Bb2121 In Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM) (KarMMa-4)

    Scottsdale/Phoenix, AZ, Jacksonville, FL

  7. Ixazomib Citrate, Lenalidomide, Dexamethasone, And Daratumumab In Treating Patients With Newly Diagnosed Multiple Myeloma

    Rochester, MN

  8. Study Evaluating The Safety And Effectiveness Of JCARH125 In Subjects With Relapsed And/or Refractory Multiple Myeloma (EVOLVE)

    Rochester, MN

  9. Study Of ISB 1342, A CD38/​CD3 Bispecific Antibody, In Subjects With Previously Treated Multiple Myeloma

    Rochester, MN

  10. Alternate Doses And Dosing Schedules Of Belantamab Mafodotin For The Treatment Of Triple-Class Recurrent And/or Refractory Multiple Myeloma

    Jacksonville, FL

.

Mayo Clinic Footer